AllAnalyst Report
logoMorningstarMarch 01, 2021

Perrigo Company plc: Perrigo Unloads Its Generic Business and Reports Softness in Its Fourth Quarter

Symbols
PRGO
Sector(s)
Healthcare
Rating
Current Price
$48.28
Fair Value
Economic Moat
Stewardship
Summary

Perrigo is the leading provider of over-the-counter generic drugs with over 100 global locations. The company was formed in 1887 as a packager of home remedies and has grown with the migration of prescriptions switching to OTC and later with strategic acquisitions. The company has a portfolio of more than 3,000 product formulations and 14,000 stock-keeping units. Most of its manufacturing and customer base reside in North America. With the most recent management change, the company announced a narrower focus on consumer wellness in conjunction with the divestiture of animal health, acquisition of Ranir Global Holdings, and plans to sell or spin off the prescription business.

Subscribe to Yahoo Finance Plus Essential for full access
Exclusive reports, detailed company profiles, and best-in-class trade insights to take your portfolio to the next level
Try it Free

Analyst Profile

Soo Romanoff

Equity Analyst
Tancrede Fulop, CFA, is an equity analyst for Morningstar Holland BV, a wholly owned subsidiary of Morningstar, Inc. He covers European utilities.Before joining Morningstar in early 2017, Fulop worked for Schlumberger Business Consulting as a financial and economist analyst. Previously, he was a senior research associate covering European utilities for Raymond James from 2011 to 2015.Fulop holds a master’s degree in finance from the University Paris II Pantheon-Assas. He also holds the Chartered Financial Analyst® designation.